Literature DB >> 10747231

A 5-year epidemiological study of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a medium- and long-stay neurological unit.

N Mangeney1, P Niel, G Paul, E Faubert, S Hue, C Dupeyron, F Louarn, G Leluan.   

Abstract

Thirty-eight different strains of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae (ESBL Kp), isolated from urine and pus samples of 38 patients hospitalized in a medium- and long-stay neurology department between 1 January 1992 and 31 December 1996, were analysed by antibiotic resistance phenotyping, DNA macrorestriction by pulsed-field electrophoresis and isoelectric focusing of beta-lactamases. An epidemiological survey was conducted to identify risk factors for infection by ESBL Kp in this setting. The 38 isolates were distributed into 13 antibiotypes, three of which predominated (13, six and six isolates). The DNA macrorestriction pattern identified 15 genotypes, four of which predominated (11, six, four and four isolates). A combination of the two typing methods revealed several epidemic clones that emerged consecutively. Two main types of ESBL (SHV-2 and CTX-1) were identified by isoelectric focusing, the former predominating. The case-control study showed that the length of hospital stay, degree of malnutrition and dependency, and urinary sphincter status were the main factors significantly associated with ESBL Kp isolation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747231     DOI: 10.1046/j.1365-2672.2000.00989.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  7 in total

1.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

2.  Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC beta-lactamase in a teaching hospital admitting disabled patients.

Authors:  Salomon Ohana; Veronique Leflon; Esthel Ronco; Martin Rottman; Didier Guillemot; Sylvie Lortat-Jacob; Pierre Denys; Georges Loubert; Marie-Helène Nicolas-Chanoine; Jean-Louis Gaillard; Christine Lawrence
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

4.  Extended-spectrum β-lactamases in Gram Negative Bacteria.

Authors:  Deepti Rawat; Deepthi Nair
Journal:  J Glob Infect Dis       Date:  2010-09

Review 5.  Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses.

Authors:  Tirza C Hendrik; Anne F Voor In 't Holt; Margreet C Vos
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

6.  Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study.

Authors:  Jérôme Fennell; Akke Vellinga; Belinda Hanahoe; Dearbhaile Morris; Fiona Boyle; Francis Higgins; Maura Lyons; Karina O'Connell; Deirbhile Keady; Martin Cormican
Journal:  BMC Infect Dis       Date:  2012-05-15       Impact factor: 3.090

7.  Combination of extracts from Aristolochia cymbifera with streptomycin as a potential antibacterial drug.

Authors:  Willer F Silva; Samyra G Cecílio; Cintia Lb Magalhães; Jaqueline Ms Ferreira; Antonio H Tótola; Jose C de Magalhaes
Journal:  Springerplus       Date:  2013-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.